April 28, 2022

Innovative Medicines Canada welcomes the Ontario budget’s investments in life sciences and innovation

Ottawa, April 28, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, issued the following statement in response to the Ontario budget released by Finance Minister Peter Bethlenfalvy today. […]

April 20, 2022

Innovative Medicines Canada Statement on the PMPRB Regulations Announcement

Ottawa, April 20, 2022 – Innovative Medicines Canada (IMC), the association representing Canada’s research-based pharmaceutical sector, issued the following statement in response to the Federal Government’s recent announcement on the […]

April 8, 2022

Innovative Medicines Canada Statement on Federal budget 2022

IMC is pleased with the ongoing commitments to increased access to innovative medicines and treatments […]

March 31, 2022

PMPRB continues to ignore the value of innovative medicines for Canadians

Ottawa, March 31, 2022 – Innovative Medicines Canada (IMC) is disappointed by the latest Patented Medicine Prices Review Board (PMPRB) Annual Report, which continues to disseminate inaccurate representation of data […]

March 24, 2022

IMC welcomes renewed commitment to a pan-Canadian approach to pharmacare

IMC welcomes the federal government’s renewed commitment to enhancing access […]